Key result
Increased levels of von Willebrand factor and soluble thrombomodulin independently predicted cardiovascular endpoints, but only von Willebrand factor predicted MI, stroke, or arterial surgery.
Why the study?
Does von Willebrand factor or soluble thrombomodulin better predict adverse cardiovascular events in subjects with peripheral or coronary atherosclerosis?
Cohort (n=111)
Does von Willebrand factor or soluble thrombomodulin better predict adverse cardiovascular events in subjects with peripheral or coronary atherosclerosis?
Von Willebrand factor is a marginally better predictor of hard cardiovascular events than soluble thrombomodulin in patients with established peripheral or coronary atherosclerosis.
Answers are grounded in this paper and cite their sources.
vWF may aid risk stratification for hard events in atherosclerosis; leaves open incremental value beyond standard factors.
Increased levels of the endothelial markers von Willebrand factor and soluble thrombomodulin have been identified as predictors of the development of adverse cardiovascular events. The purpose of this study was to determine which of these markers is the best predictor of such events. Both markers were measured using enzyme-linked immunosorbent assays in 111 subjects at high risk of cardiovascular disease (50 with peripheral atherosclerosis and 66 who had suffered myocardial infarction). After a mean of 46 months, a follow-up investigation was performed and cardiovascular end-points (myocardial infarction, stroke, measured progression of peripheral atherosclerosis, arterial surgery, etc.) were noted. Multivariate analysis revealed that both markers were independent predictors among the 54 subjects who suffered any one of the cardiovascular end-points (P < 0.01). However, only an increased level of von Willebrand factor predicted the outcome among the 39 subjects who suffered a myocardial infarction, stroke or arterial surgery (P < 0.05). We conclude that von Willebrand factor is a marginally better predictor of cardiovascular events than soluble thrombomodulin.
No takes yet. Share an insight, caveat, or question.
Blann et al. (1999) conducted a cohort in peripheral or coronary atherosclerosis (n=111). von Willebrand factor and soluble thrombomodulin was evaluated on cardiovascular end-points (myocardial infarction, stroke, measured progression of peripheral atherosclerosis, arterial surgery, etc.) (p=<0.01). Increased levels of von Willebrand factor and soluble thrombomodulin independently predicted cardiovascular endpoints, but only von Willebrand factor predicted MI, stroke, or arterial surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: